Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19

Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19

<b>Background:</b> Coronavirus disease 19 (COVID-19) can develop into a severe respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major pathological finding in autopsies explaining O<sub>2</sub> diffusion failure and hypoxemia. Only d...

Full description

Bibliographic Details
Main Authors: Eli Mansour, Andre C. Palma, Raisa G. Ulaf, Luciana C. Ribeiro, Ana Flavia Bernardes, Thyago A. Nunes, Marcus V. Agrela, Bruna Bombassaro, Milena Monfort-Pires, Rafael L. Camargo, Eliana P. Araujo, Natalia S. Brunetti, Alessandro S. Farias, Antônio Luís E. Falcão, Thiago Martins Santos, Plinio Trabasso, Rachel P. Dertkigil, Sergio S. Dertkigil, Maria Luiza Moretti, Licio A. Velloso
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Viruses
Subjects:
angiotensin converting enzyme 2
bradykinin
coronavirus
inflammation
lung
Online Access:https://www.mdpi.com/1999-4915/13/2/309

Internet

https://www.mdpi.com/1999-4915/13/2/309

Similar Items